HRS/EHRA/APHRS/LAHRS/ACC/AHA Worldwide Practice Update for Telehealth and Arrhythmia Monitoring During and After a Pandemic
暂无分享,去创建一个
M. Chung | H. Heidbuchel | C. Albert | A. Russo | L. Epstein | H. Ghanbari | N. Marrouche | T. Ngarmukos | P. Varosy | N. Varma | E. Arbelo | E. Stecker | G. Conte | E. Saad | L. Aguinaga | D. Lakkireddy | K. Sandau | Janet K. Han | Luis C. Saenz Morales | Lilas Dagher | Arun R. Sridhar | Jong-il Choi | He Huang
[1] Jerrilyn Jones,et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State , 2020, The Journal of Emergency Medicine.
[2] David R. Holtgrave,et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State , 2020, The Journal of Emergency Medicine.
[3] G. Hripcsak,et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 , 2020, The New England journal of medicine.
[4] Michael A. Spinelli,et al. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin , 2020, Heart Rhythm.
[5] L. Epstein,et al. Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection , 2020, Circulation. Arrhythmia and electrophysiology.
[6] M. Ueda,et al. Remote Management of Pacemaker Patients With Biennial In-Clinic Evaluation , 2020, Circulation. Arrhythmia and electrophysiology.
[7] Nathaniel Hupert,et al. Clinical Characteristics of Covid-19 in New York City , 2020, The New England journal of medicine.
[8] D. Mann,et al. COVID-19 Clinical Trials , 2020, JACC: Basic to Translational Science.
[9] M. Eslami,et al. Transient complete heart block in a patient with critical COVID-19 , 2020, European heart journal.
[10] Erwan L'Her,et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19 , 2020, The New England journal of medicine.
[11] C. Tondo,et al. Cardiac and arrhythmic complications in patients with COVID‐19 , 2020, Journal of cardiovascular electrophysiology.
[12] J. Healey,et al. Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society , 2020, Canadian Journal of Cardiology.
[13] P. Noseworthy,et al. Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19) , 2020, Mayo Clinic Proceedings.
[14] L. Epstein,et al. Inpatient use of mobile continuous telemetry for COVID-19 patients treated with hydroxychloroquine and azithromycin , 2020, HeartRhythm Case Reports.
[15] Reyma Raju,et al. How to protect the protectors: 10 lessons to learn for doctors fighting the COVID-19 coronavirus , 2020, Medical Journal Armed Forces India.
[16] Zhan Zhang,et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial , 2020, medRxiv.
[17] Roberto Maroldi,et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). , 2020, JAMA cardiology.
[18] Tao Guo,et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) , 2020, JAMA cardiology.
[19] X. Bian,et al. [A pathological report of three COVID-19 cases by minimally invasive autopsies]. , 2020, Zhonghua bing li xue za zhi = Chinese journal of pathology.
[20] J. Hollander,et al. Virtually Perfect? Telemedicine for Covid-19. , 2020, The New England journal of medicine.
[21] K. Kim,et al. What Is COVID-19? , 2020, Frontiers for Young Minds.
[22] Shao-hua Hu,et al. Online mental health services in China during the COVID-19 outbreak , 2020, The Lancet Psychiatry.
[23] Yan Zhao,et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.
[24] T. Bunch,et al. HRS White Paper on interoperability of data from cardiovascular implantable electronic devices (CIEDs). , 2019, Heart Rhythm.
[25] P. Sager,et al. Assessment of Multi‐Ion Channel Block in a Phase I Randomized Study Design: Results of the CiPA Phase I ECG Biomarker Validation Study , 2019, Clinical pharmacology and therapeutics.
[26] N. White,et al. The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review , 2018, BMC Medicine.
[27] D. Yoon,et al. Risk Evaluation of Azithromycin-Induced QT Prolongation in Real-World Practice , 2018, BioMed research international.
[28] Aarti S. Dalal,et al. Can smartphone wireless ECGs be used to accurately assess ECG intervals in pediatrics? A comparison of mobile health monitoring to standard 12-lead ECG , 2018, PloS one.
[29] L. Epstein,et al. Factors Influencing the Decision to Proceed to Firmware Upgrades to Implanted Pacemakers for Cybersecurity Risk Mitigation. , 2018, Circulation.
[30] Peter J. Schwartz,et al. A wearable remote monitoring system for the identification of subjects with a prolonged QT interval or at risk for drug-induced long QT syndrome. , 2018, International journal of cardiology.
[31] G. Tomlinson,et al. Electrocardiogram abnormalities related to anti-malarials in systemic lupus erythematosus. , 2018, Clinical and experimental rheumatology.
[32] Wojciech Zareba,et al. 2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. , 2017, Heart rhythm.
[33] G. Hindricks,et al. Daily remote monitoring of implantable cardioverter-defibrillators: insights from the pooled patient-level data from three randomized controlled trials (IN-TIME, ECOST, TRUST) , 2017, European heart journal.
[34] Long Chen,et al. Electrophysiologic Studies on the Risks and Potential Mechanism Underlying the Proarrhythmic Nature of Azithromycin , 2017, Cardiovascular Toxicology.
[35] B. Lindsay,et al. Association Between Off-site Central Monitoring Using Standardized Cardiac Telemetry and Clinical Outcomes Among Non-Critically Ill Patients. , 2016, JAMA.
[36] Dwight Reynolds,et al. Comparison of QT Interval Readings in Normal Sinus Rhythm Between a Smartphone Heart Monitor and a 12‐Lead ECG for Healthy Volunteers and Inpatients Receiving Sotalol or Dofetilide , 2016, Journal of cardiovascular electrophysiology.
[37] Haipeng Xiao,et al. The Role of Macrolide Antibiotics in Increasing Cardiovascular Risk. , 2015, Journal of the American College of Cardiology.
[38] R. Ohannessian,et al. Telemedicine: Potential applications in epidemic situations , 2015, European Research in Telemedicine / La Recherche Européenne en Télémédecine.
[39] Renato Pietro Ricci,et al. HRS Expert Consensus Statement on remote interrogation and monitoring for cardiovascular implantable electronic devices. , 2015, Heart rhythm.
[40] J. Sin,et al. Azithromycin and the Risk of Cardiovascular Complications , 2014, Journal of pharmacy practice.
[41] H. Heidbuchel,et al. EuroEco (European Health Economic Trial on Home Monitoring in ICD Patients): a provider perspective in five European countries on costs and net financial impact of follow-up with or without remote monitoring , 2014, European heart journal.
[42] M. Peller,et al. Kardia Mobile applicability in clinical practice: A comparison of Kardia Mobile and standard 12-lead electrocardiogram records in 100 consecutive patients of a tertiary cardiovascular care center , 2013, Cardiology journal.
[43] B. Stambler,et al. Same-day discovery of implantable cardioverter defibrillator dysfunction in the TRUST remote monitoring trial: influence of contrasting messaging systems , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[44] Renato Pietro Ricci,et al. Telemedicine and cardiac implants: what is the benefit? , 2012, European heart journal.
[45] C Michael Stein,et al. Azithromycin and the risk of cardiovascular death. , 2012, The New England journal of medicine.
[46] B. Kuhn,et al. Thorough QT/QTc study of tocilizumab after single-dose administration at therapeutic and supratherapeutic doses in healthy subjects. , 2011, International journal of clinical pharmacology and therapeutics.
[47] R. Schweikert,et al. Efficacy and Safety of Automatic Remote Monitoring for Implantable Cardioverter-Defibrillator Follow-Up: The Lumos-T Safely Reduces Routine Office Device Follow-Up (TRUST) Trial , 2010, Circulation.
[48] U. Moretti,et al. Antimicrobials and the Risk of Torsades de Pointes , 2010, Drug safety.
[49] A. Dreisbach,et al. Randomized Dose-Ranging Controlled Trial of AQ-13, a Candidate Antimalarial, and Chloroquine in Healthy Volunteers , 2007, PLoS clinical trials.
[50] I. Cygankiewicz,et al. The Cardiac Safety of Chloroquine Phosphate Treatment in Patients with Systemic Lupus Erythematosus: The Influence on Arrhythmia, Heart Rate Variability and Repolarization Parameters , 2006, Lupus.
[51] Sanjit Bagchi,et al. Telemedicine in Rural India , 2006, PLoS medicine.
[52] R. Costa,et al. Cardiac damage from chronic use of chloroquine: a case report and review of the literature. , 2002, Arquivos brasileiros de cardiologia.
[53] R. F. I. Smith,et al. Governance , 2001, The Corporation as a Protagonist in Global History, c. 1550-1750.
[54] L. Rimmer,et al. Comparison of 2 methods of measuring the QT interval. , 1998, American journal of critical care : an official publication, American Association of Critical-Care Nurses.
[55] L. Rimmer. Bedside monitoring of the QT interval. , 1998, American journal of critical care : an official publication, American Association of Critical-Care Nurses.
[56] Richard L. Verrier,et al. ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiacmonitoring / telemetry , 2017 .
[57] Janet Richards,et al. Information governance. , 2006, Nursing standard (Royal College of Nursing (Great Britain) : 1987).
[58] K. Jenpanich,et al. [Drug administration]. , 1976, Thai journal of nursing.